IDH1/2 Inhibitor

LY3410738

IDH1 Inhibitor

Waitkus MS, et al1

Target
The enzyme isocitrate dehydrogenase (IDH1) is mutated in a variety of cancers, including acute myeloid leukemia (AML), cholangiocarcinoma, chondrosarcoma, and glioma.2-5 These mutations are typically somatic gain-of-function mutations located in arginine 132 (R132) that grant IDH1 the ability to produce 2-hydroxyglutarate (2-HG).6 2-HG is an oncometabolite that promotes tumor development by inhibiting enzymes that maintain normal DNA and histone methylation, leading to hypermethylation associated with transcriptional dysregulation.6,7 As a result, IDH1-mutated cells become blocked in a progenitor-like state and contribute to tumor development both directly through cellular self-renewal and indirectly through cooperation with other oncogenic drivers.7
Molecule
LY3410738 is a potent, selective, and covalent inhibitor of mutant IDH1 that has been shown in vitro and in vivo to rapidly inactivate mutant IDH1 and inhibit 2-HG production without impacting wild-type IDH1.8
Clinical Development
LY3410738 is being investigated in clinical trials in patients with IDH1/2 advanced hematologic malignancies or advanced solid tumors.

References

  1. Waitkus MS, et al. Cancer Cell. 2018;34(2):186-195.
  2. Gross S, et al. J Exp Med. 2010;207(2):339-344.
  3. Borger DR, et al. Oncologist. 2012;17(1):72-79.
  4. Amary MF, et al. J Pathol. 2011;224(3):334-343.
  5. Yan H, et al. N Engl J Med. 2009;360(8):765-773.
  6. Losman JA, et al. Science. 2013;339(6127):1621-1625.
  7. Lu C, et al. Nature. 2012;483(7390):474-478.
  8. Brooks N, et al. AACR Annual Meeting; March 29-April 3, 2019; Atlanta, GA. Abstract LB274.
Clinical Development
LY3410738 is being investigated in clinical trials in patients with IDH1/2 advanced hematologic malignancies or advanced solid tumors.

References

  1. Waitkus MS, et al. Cancer Cell. 2018;34(2):186-195.
  2. Gross S, et al. J Exp Med. 2010;207(2):339-344.
  3. Borger DR, et al. Oncologist. 2012;17(1):72-79.
  4. Amary MF, et al. J Pathol. 2011;224(3):334-343.
  5. Yan H, et al. N Engl J Med. 2009;360(8):765-773.
  6. Losman JA, et al. Science. 2013;339(6127):1621-1625.
  7. Lu C, et al. Nature. 2012;483(7390):474-478.
  8. Brooks N, et al. AACR Annual Meeting; March 29-April 3, 2019; Atlanta, GA. Abstract LB274.

Need additional information or have a question:

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

DISCOVER OTHER MOLECULES

VEGF Receptor-2 Antagonist

Learn More

RET Inhibitor

Learn More

RET Inhibitor

Learn More